Early use of canakinumab to prevent mechanical ventilation in select COVID-19 patients: A retrospective, observational analysis

INTRODUCTION: The fully-human monoclonal anti-interleukin (IL)-1β antibody canakinumab may inhibit the production of inflammatory mediators in patients with coronavirus disease 2019 (COVID-19) and the hyperinflammatory response potentially leading to acute respiratory distress syndrome. OBJECTIVES:...

Descripción completa

Detalles Bibliográficos
Autores principales: Mastroianni, Antonio, Greco, Sonia, Chidichimo, Luciana, Urso, Filippo, Greco, Francesca, Mauro, Maria V, Vangeli, Valeria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725043/
https://www.ncbi.nlm.nih.gov/pubmed/34928722
http://dx.doi.org/10.1177/20587384211059675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725043/
https://www.ncbi.nlm.nih.gov/pubmed/34928722
http://dx.doi.org/10.1177/20587384211059675

Ejemplares similares